Evidence-based medicine and its standard practice When Archibald Cochrane formulated his vision for evidence-based medicine (EBM), it was driven by an absence of reliable, robust evidence supporting frequently accepted medical interventions. His observations provoked...
Introduction The NICE Medical Technologies Evaluation Programme (MTEP) evaluates novel medical devices and diagnostics for use within the National Health Service (NHS). There are currently 3 outputs from the programme: medical technologies guidance (MTGs), diagnostics...
A poster on this topic was presented at ISPOR Europe 2019. This blog post provides an overview of our findings.The abstract is available here. In previous blog posts, we explored the origins of NICE’s Highly Specialised Technologies (HST) process and compared it with...
In a previous post, we discussed the origins of the NICE Highly Specialised Technologies (HST) process for the evaluation of therapies for rare diseases. In this blog, we examine the key differences between the Single Technology Appraisal (STA) and the HST processes....
Origins of the Highly Specialised Technologies (HST) process Treatments for very rare conditions represent a unique challenge to payers. Extremely low patient numbers mean that often only Phase 1/2 trial data are available, and that natural history, quality of life...
